ABSTRACT
The impact on patients’ lives is far-reaching and depends on a number of factors such as clinical manifestations, comorbidities, staging, treatment side effects, and requirements as well personal responsibilities. In addition, although TKIs are less toxic than traditional systemic chemotherapy, they are commonly associated with specific side effects. Several genetic alterations have been clarified as therapeutic targets, namely those occurring in the EGFR gene and ALK gene rearrangements. Target therapies have significantly improved patients’ outcomes with more favorable tolerability compared to systemic chemotherapy. Nonetheless, although several investigations have been made in this field, in recent years, further, and increasingly deepen in vivo studies are needed to confirm their therapeutic benefits and safety profiles.
